http://orcid.org/0000-0003-2229-1200
References
- Palacios S, Mejía A, Neyro JL. Treatment of the genitourinary syndrome of menopause. Climacteric 2015;18 (Suppl 1):23–9
- Palacios S, Castelo-Branco C, Currie H, et al. Update on management of genitourinary syndrome of menopause: A practical guide. Maturitas 2015;82:308–13
- Portman DJ, Gass ML. Vulvovaginal Atrophy Terminology Consensus Conference Panel. Genitourinary syndrome of menopause: new terminology for vulvovaginal atrophy from the International Society for the Study of Women's Sexual Health and the North American Menopause Society. Menopause 2014;21:1063–8
- Martin-Alguacil N, Pfaff DW, Kow LM, Schober JM. Oestrogen receptors and their relation to neural receptive tissue of the labia minora. BJU Int 2008;101:1401–6
- Sawczuk B, Gołębiewska M, Mazurek A, Chyczewski L. Immunohistochemical evaluation of oestrogen receptors α and β in epithelium of the vaginal mucous membrane in women after oestrogen therapy. Prz Menopauzalny 2017;16:12–18
- Blakeman PJ, Hilton P, Bulmer JN. Oestrogen and progesterone receptor expression in the female lower urinary tract, with reference to oestrogen status. BJU Int 2000;86:32–8
- Baldassarre M, Perrone AM, Giannone FA, et al. Androgen receptor expression in the human vagina under different physiological and treatment conditions. Int J Impot Res 2013;25:7–11
- Anderson DJ, Marathe J, Pudney J. The structure of the human vaginal stratum corneum and its role in immune defense. Am J Reprod Immunol 2014;71:618–23
- Palacios S. Managing urogenital atrophy. Maturitas 2009;63:315–18
- Brotman RM, Shardell MD, Gajer P, et al. Association between the vaginal microbiota, menopause status, and signs of vulvovaginal atrophy. Menopause 2018;25:1321–30
- http://www.fda.gov/downloads/Drugs/GuidanceComplianceRegulatoryInformation/Guidances
- Palacios S, Cancelo MJ, Castelo Branco C, et al. Vulvar and vaginal atrophy as viewed by the Spanish REVIVE participants: symptoms, management and treatment perceptions. Climacteric 2017;20:55–61
- Bachmann G. Urogenital ageing: an old problem newly recognized. Maturitas 1995;22:S1–S5
- McEndree B. Clinical application of the vaginal maturation index. Nurse Pract 1999;24:48, 51–2, 55–6
- Palacios S, González SP, Cancelo MJ. Is pH a vaginal health marker? Phemale Study. Minerva Ginecol 2018;70:138–43
- Zerbinati N, Serati M, Origoni M, et al. Microscopic and ultrastructural modifications of postmenopausal atrophic vaginal mucosa after fractional carbon dioxide laser treatment. Lasers Med Sci 2015;30:429–36
- Salvatore S, Leone Roberti Maggiore U, Athanasiou S, et al. Histological study on the effects of microablative fractional CO2 laser on atrophic vaginal tissue: an ex vivo study. Menopause 2015;22:845–9
- Vanaman Wilson MJ, Bolton J, Jones IT, et al. Histologic and clinical changes in vulvovaginal tissue after treatment with a transcutaneous temperature-controlled radiofrequency device. Dermatol Surg 2018;44:705–13
- Shafik A, El Sibai O, Shafik AA, Ahmed I, Mostafa RM. The electrovaginogram: study of the vaginal electric activity and its role in the sexual act and disorders. Arch Gynecol Obstet 2004;269:282–6
- Shafik A. Study of the uterine response to vaginal distension: the 'vagino-uterine reflex'. Gynecol Obstet Invest 1997;44:265–9
- Laan E, van Lunsen RH, Everaerd W. The effects of tibolone on vaginal blood flow, sexual desire and arousability in postmenopausal women. Climacteric 2001;4:28–41
- Selimović S, Dokmeci MR, Khademhosseini A. Organs-on-a-chip for drug discovery. Curr Opin Pharmacol 2013;13:829–33